A new resistance mechanism to cisplatin?

Drug Resistance Updates

Volumn 3, Issue 3, 2000, Pages 139-141

  Kelland, Lloyd R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; MESSENGER RNA; METHOTREXATE; PACLITAXEL; TYROSINE;

APOPTOSIS; CANCER RESISTANCE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MELANOMA; MOLECULAR CLONING; MUTAGENESIS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW;

EID: 0033864687     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2000.0132     Document Type: Article

References (9)

1. New approaches to the systemic treatment of melanoma
2. Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): Therapeutic implications
3. Retrovirat insertional mutagenesis as a strategy for the identification of genes associated with cis-diamminedichloroplatinum(II) resistance
4. Recent insights into platinum drug resistance in cancer
5. BCL-2 antisense therapy chemosensitizes human melanoma in SCID mice
6. Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression
7. Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma
8. Characterization of the p53 tumor suppressor pathway in celt lines of the National Cancer Institute anticancer drug screen and correlations with the growth inhibitory potency of 123 anticancer agents
9. Decreased accumulation of [C-14]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake